Defense-oriented inflammatory reactivity supports survival at younger age, but might contribute to health impairments in modern, aging societies. The IL-1 cytokines are highly conserved and regulated, pleiotropic mediators of inflammation, essential to respond adequately to infection and tissue damage, but also with potential host damaging effects when left unresolved. In this review, we discuss how continuous low-level IL-1 signaling contributes to aging-associated hematopoietic stem and progenitor cell (HSPC) functional impairments and how this inflammatory selective pressure acts as a driver of more profound hematological alterations, such as clonal hematopoiesis of indeterminate potential (CHIP), and to overt HSPC diseases, like myeloproliferative and myelodysplastic neoplasia as well as acute myeloid leukemia. Based on this, we outline how IL-1 pathway inhibition might be utilized to prevent or treat "inflamm-aging" associated HSPC pathologies.
Research Article|
May 23, 2024
IL-1 in Aging and Pathologies of Hematopoietic Stem Cells
Markus Gabriel Manz,
University Hospital Zurich and University of Zurich, Zurich, Switzerland
* Corresponding Author; email: markus.manz@usz.ch
Search for other works by this author on:
Francisco Caiado
Francisco Caiado
University Hospital Zurich and University of Zurich, Zurich, Switzerland
Search for other works by this author on:
Blood blood.2023023105.
Article history
Submitted:
February 28, 2024
Revision Received:
May 1, 2024
Accepted:
May 13, 2024
Citation
Markus Gabriel Manz, Francisco Caiado; IL-1 in Aging and Pathologies of Hematopoietic Stem Cells. Blood 2024; blood.2023023105. doi: https://doi.org/10.1182/blood.2023023105
Download citation file: